-
公开(公告)号：US20210094998A1
公开(公告)日：2021-04-01
申请号：US17085128
申请日：2020-10-30
Applicant: Janssen Pharmaceutica NV
Inventor： Mark MACIELAG , Raymond J. PATCH , Rui ZHANG , Martin A. CASE , Mark J. WALL , Yue-Mei ZHANG , Shamina M. RANGWALA , James N. LEONARD , Raul C. CAMACHO , Michael J. HUNTER , Katharine E. D'AQUINO , Wilson EDWARDS , Ronald V. SWANSON , Wenying JIAN , Ellen CHI
IPC: C07K14/575 , A61K47/68 , C07K16/24 , A61K9/00 , A61K38/17 , A61K38/26 , C07K1/06 , C07K1/107 , A61K47/64 , A61P3/10 , A61K49/00 , C07K1/12 , C07K1/18 , C07K5/02 , A61K47/60 , A61P3/08 , A61P3/00 , A61P3/04 , A61P3/06 , A61K38/22 , A61K45/06 , C07K16/00
Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
-
公开(公告)号：US20210253661A1
公开(公告)日：2021-08-19
申请号：US15733776
申请日：2019-04-24
Applicant: Janssen Pharmaceutica NV
Inventor： Yue-Mei ZHANG , Raul CAMACHO , Martin A. CASE , Ellen CHI , Suzanne EDAVETTAL , Wilson EDWARDS , Lisa NORQUAY , Mark J. WALL , Rui ZHANG , Songmao ZHENG
IPC: C07K14/605 , C07K14/575 , A61K47/64 , A61P3/04 , A61K9/00
Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
-
3.发明申请公开(公告)号：US20190298849A1
公开(公告)日：2019-10-03
申请号：US16344174
申请日：2017-10-26
Applicant: Janssen Pharmaceutica NV
Inventor： Mark MACIELAG , Raymond J. PATCH , Rui ZHANG , Martin A. CASE , Shamina M. RANGWALA , James N. LEONARD , Raul C. CAMACHO , Michael J. HUNTER , Katharine E. D'AQUINO , Wilson EDWARDS , Ronald V. SWANSON , Wenying JIAN , Yue-Mei ZHANG , Mark J. WALL , Ellen CHI
Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
-
公开(公告)号：US20150239844A1
公开(公告)日：2015-08-27
申请号：US14615560
申请日：2015-02-06
Applicant: JANSSEN PHARMACEUTICA NV
Inventor： Bart DeCORTE , Mark MACIELAG , Michael GRECO , Yue-Mei ZHANG , Christopher TELEHA
IPC: C07D215/44 , C07D409/14 , C07D409/06 , C07D405/14 , C07D401/12 , C07D401/14 , C07D417/14 , C07D417/06
CPC classification number: C07D215/44 , C07D215/06 , C07D215/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/06 , C07D409/14 , C07D417/06 , C07D417/14
Abstract: The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
Abstract translation: 本发明涉及喹啉衍生物，含有所述衍生物的药物组合物及其在治疗由CB-1受体介导的病症和病症中的用途; 更具体地，涉及治疗响应于CB-1受体反向激动作用的病症和病症。 例如，本发明的化合物可用于治疗代谢紊乱。
-
公开(公告)号：US20250026803A1
公开(公告)日：2025-01-23
申请号：US18904962
申请日：2024-10-02
Applicant: Janssen Pharmaceutica NV
Inventor： Mark MACIELAG , Raymond J. PATCH , Rui ZHANG , Martin A. CASE , Mark J. WALL , Yue-Mei ZHANG , Shamina M. RANGWALA , James N. LEONARD , Raul C. CAMACHO , Michael J. HUNTER , Katharine E. D'AQUINO , Wilson EDWARDS , Ronald V. SWANSON , Wenying JIAN , Ellen CHI
IPC: C07K14/575 , A61K9/00 , A61K38/00 , A61K38/17 , A61K38/22 , A61K38/26 , A61K39/00 , A61K45/06 , A61K47/60 , A61K47/64 , A61K47/68 , A61K49/00 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/08 , A61P3/10 , C07K1/06 , C07K1/107 , C07K1/12 , C07K1/18 , C07K5/02 , C07K16/00 , C07K16/24
Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
-
Patent Agency Ranking
公开(公告)号：US20210206822A1
公开(公告)日：2021-07-08
申请号：US17168325
申请日：2021-02-05
Applicant: Janssen Pharmaceutica NV
Inventor： Mark MACIELAG , Raymond J. PATCH , Rui ZHANG , Martin A. CASE , Mark J. WALL , Yue-Mei ZHANG
IPC: C07K14/575 , A61K47/68 , C07K16/24 , A61K9/00 , A61K38/17 , A61K38/26 , C07K1/06 , C07K1/107 , A61K47/64 , A61P3/10 , A61K49/00 , C07K1/12 , C07K1/18 , C07K5/02 , A61K47/60 , A61P3/08 , A61P3/00 , A61P3/04 , A61P3/06 , A61K38/22 , A61K45/06 , C07K16/00
Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
-
7.发明申请公开(公告)号：US20190330296A1
公开(公告)日：2019-10-31
申请号：US16392898
申请日：2019-04-24
Applicant: Janssen Pharmaceutica NV
Inventor： Yue-Mei ZHANG , Raul C. CAMACHO , Martin A. CASE , Ellen CHI , Suzanne EDAVETTAL , Wilson EDWARDS , Lisa NORQUAY , Mark J. WALL , Rui ZHANG , Songmao ZHENG
Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
-
公开(公告)号：US20240018208A1
公开(公告)日：2024-01-18
申请号：US18343689
申请日：2023-06-28
Applicant: Janssen Pharmaceutica NV
Inventor： Mark MACIELAG , Raymond J. PATCH , Rui ZHANG , Martin A. CASE , Mark J. WALL , Yue-Mei ZHANG
IPC: C07K14/575 , A61K47/68 , C07K16/24 , A61K9/00 , A61K38/17 , A61K38/26 , C07K1/06 , C07K1/107 , A61K47/64 , A61P3/10 , A61K49/00 , C07K1/12 , C07K1/18 , C07K5/02 , A61K47/60 , A61P3/08 , A61P3/00 , A61P3/04 , A61P3/06 , A61K38/22 , A61K45/06 , C07K16/00
CPC classification number: C07K14/575 , A61K47/6845 , C07K16/24 , A61K47/68 , A61K47/6883 , A61K9/0019 , A61K38/1709 , A61K38/26 , C07K1/061 , C07K1/1072 , C07K14/57545 , A61K47/64 , A61P3/10 , A61K38/17 , A61K49/0032 , A61K49/0052 , A61K49/0056 , C07K1/12 , C07K1/18 , C07K5/0205 , A61K47/60 , A61P3/08 , A61P3/00 , A61P3/04 , A61P3/06 , A61K38/22 , A61K45/06 , A61K47/6811 , C07K16/00 , C07K2317/14 , C07K2317/56 , C07K2317/71 , C07K2317/33 , A61K38/00
Abstract: The present invention comprises compounds of Formula I.
wherein:
Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.-
9.发明公开公开(公告)号：US20230365644A1
公开(公告)日：2023-11-16
申请号：US18154020
申请日：2023-01-12
Applicant: Janssen Pharmaceutica NV
Inventor： Mark MACIELAG , Raymond J. PATCH , Rui ZHANG , Martin A. CASE , Shamina M. RANGWALA , James N. LEONARD , Raul C. CAMACHO , Michael J. HUNTER , Katharine E. D'AQUINO , Wilson EDWARDS , Ronald V. SWANSON , Wenying JIAN , Yue-Mei ZHANG , Mark WALL , Ellen CHI
IPC: C07K14/575 , A61K47/68 , C07K16/24 , A61K9/00 , A61K38/17 , A61K38/26 , C07K1/06 , C07K1/107 , A61K47/64 , A61P3/10 , A61K49/00 , C07K1/12 , C07K1/18 , C07K5/02 , A61K47/60 , A61P3/08 , A61P3/00 , A61P3/04 , A61P3/06 , A61K38/22 , A61K45/06 , C07K16/00
CPC classification number: C07K14/575 , A61K47/6845 , C07K16/24 , A61K47/68 , A61K47/6883 , A61K9/0019 , A61K38/1709 , A61K38/26 , C07K1/061 , C07K1/1072 , C07K14/57545 , A61K47/64 , A61P3/10 , A61K38/17 , A61K49/0032 , A61K49/0052 , A61K49/0056 , C07K1/12 , C07K1/18 , C07K5/0205 , A61K47/60 , A61P3/08 , A61P3/00 , A61P3/04 , A61P3/06 , A61K38/22 , A61K45/06 , A61K47/6811 , C07K16/00 , C07K2317/14 , C07K2317/56 , C07K2317/71 , C07K2317/33 , A61K38/00
Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
-
公开(公告)号：US20190367577A1
公开(公告)日：2019-12-05
申请号：US16542751
申请日：2019-08-16
Applicant: Janssen Pharmaceutica NV
Inventor： Mark MACIELAG , Raymond J. PATCH , Rui ZHANG , Martin A. CASE , Shamina M. RANGWALA , James N. LEONARD , Raul C. CAMACHO , Michael J. HUNTER , Katharine E. D'AQUINO , Wilson EDWARDS , Ronald V. SWANSON , Wenying JIAN , Yue-Mei ZHANG , Mark J. WALL , Ellen CHI
IPC: C07K14/575 , A61K47/64 , A61P3/10 , A61K38/17 , A61K49/00 , C07K1/12 , C07K1/18 , C07K5/02 , A61K47/60 , A61P3/08 , A61P3/00 , A61P3/04 , A61P3/06 , A61K38/22 , A61K45/06 , A61K47/68 , C07K16/00
Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.053 seconds)
